ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
06/03/2026
Back to search
Official data from USPTO
BOSTON PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
24
Latest update
06/04/2026
Trademark type
Combined
Nice classes
42
Filing date
12/20/2023
Registration date
01/21/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/21/2025
Last transaction
06/04/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
12/04/2023
First use in commerce
12/04/2023
Drawing code
3
Owner type
03
Owner location
WILMINGTON, DE, US
Examiner
GALLOWAY, JAMILLA ESPY
Law office
N30
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the word "BOSTON" in stylized capital letters above the word "PHARMACEUTICALS" also in stylized letters and to the right consists of a tree design.
Holders and representatives
Holders
BP ASSET IX, INC.
Boston Pharmaceuticals, Inc.
Representatives
Camille M. Miller Cozen O'Connor
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Research and development in the pharmaceutical and biotechnology fields; pharmaceutical drug development services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials
Publications
History of USPTO decisions and trademark events.
24 publications found
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/21/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
01/21/2025
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
10/30/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
10/30/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
10/29/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
10/29/2024
IUAF
USE AMENDMENT FILED
08/28/2024
EISU
TEAS STATEMENT OF USE RECEIVED
08/28/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
08/27/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/02/2024
PUBO
PUBLISHED FOR OPPOSITION
07/02/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/12/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/25/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/24/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/24/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/24/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/24/2024
GNRT
NON-FINAL ACTION E-MAILED
05/24/2024
CNRT
NON-FINAL ACTION WRITTEN
05/24/2024
DOCK
ASSIGNED TO EXAMINER
05/23/2024
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
04/13/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/13/2024
NWAP
NEW APPLICATION ENTERED
12/20/2023
Continuous trademark protection
Get notified about every new filing that threatens BOSTON PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.